Satish Eknath Bahekar*

Department of Pharmacology, Government Medical College, India

*Corresponding Author:Satish Eknath Bahekar, Department of Pharmacology, Government Medical College, India.

Received: November 10, 2025; Published: November 19, 2025

Abstract

The COVID-19 pandemic compelled medicine to evolve at a pace unparalleled in modern history, transforming the way therapeutics are developed, tested, approved, and delivered. In this post-pandemic era, the global scientific community faces a dual challenge: sustaining the momentum of innovation while rebuilding trust, equity, and preparedness within therapeutic systems.

References

1. Polack FP., et al. “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine”. The New England Journal of Medicine27 (2020): 2603-2615.
2. Kalil AC. “Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics”. JAMA19 (2021): 1897-1898.
3. Dolgin E. “The tangled history of mRNA vaccines”. Nature7876 (2021): 318-324.
4. Topol EJ. “Digital health and the future of medicine: progress, pitfalls, and promise”. Nature Medicine12 (2021): 2009-2014.
5. Gereffi G. “What does the COVID-19 pandemic teach us about global value chains? The case of medical supplies”. Journal of International Business Policy3 (2020): 287-301.
6. So AD and Woo J. “Reserving coronavirus disease 2019 vaccines for global access: cross-sectional analysis”. BMJ 371 (2020): m4750.

Citation

Citation: Satish Eknath Bahekar. “Post-Pandemic Therapeutics: Reimagining Resilience in Global Health". Acta Scientific Pharmaceutical Sciences 9.12 (2025): 01-02.

Copyright

Copyright: © 2025 Satish Eknath Bahekar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.